Soligenix, Inc.
NASDAQSNGX enters the final day of April as a fundamentally different story than it was a week ago — a Phase 3 futility call wiped out three-quarters of its market value in a single session. The catalyst is unambiguous. On April 28, Soligenix's independent Data Monitoring Committee recommended halting the Phase 3 FLASH2 trial of HyBryte (synthetic hypericin) in cutaneous T-cell lymphoma…
SNGX short interest surges 52% in one week to 7.98% of float, highest level since late March.
Snapshot as of 8 May 2026
SNGX enters the final day of April as a fundamentally different story than it was a week ago — a Phase 3 futility call wiped out three-quarters of its market value in a single session. The catalyst is unambiguous. On…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SNGX — free to start on ORTEX.
Sign up for free →Open SNGX on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live SNGX data →